Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
482 results about "Fucose" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Fucose is a hexose deoxy sugar with the chemical formula C₆H₁₂O₅. It is found on N-linked glycans on the mammalian, insect and plant cell surface. Fucose is the fundamental sub-unit of the seaweed polysaccharide fucoidan. The α(1→3) linked core of fucose is a suspected carbohydrate antigen for IgE-mediated allergy.
Cells of which genome is modified
InactiveUS20040110704A1Raise the ratioDecreased and deleted activityAntibacterial agentsAntipyreticGlycosideN-Acetylglucosamine
A cell in which genome is modified so as to have a more decreased or deleted activity of an enzyme relating to modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through alpha-bond in a complex N-glycoside-linked sugar chain than its parent cell, and a process for producing an antibody composition using the cell.
Owner:KYOWA HAKKO KOGYO CO LTD
Production of galactosylated glycoproteins in lower eukaryotes
InactiveUS20060040353A1Reducing and eliminating activityEfficient workFungiSugar derivativesUDP galactoseSialic acid
The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal β-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.
Owner:GLYCOFI
Fused Protein Composition
InactiveUS20080241884A1Strong cytotoxicityReduce in quantityAntibacterial agentsPeptide/protein ingredientsFucoseDrug
A fusion protein composition of an antibody Fc region which is useful as a medicament in which effector function is improved is desired.The present invention provides a fusion protein composition comprising a fusion protein molecule of an antibody Fc region having complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant producing the fusion protein composition; a process for producing the fusion protein composition; and a medicament comprising the fusion protein composition.
Owner:KYOWA HAKKO KIRIN CO LTD
Glycoprotein compositions
InactiveUS20070020260A1Improve bindingEnhance ADCCAntibacterial agentsAntimycoticsCarbohydrate structureBiology
The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.
Owner:GENENTECH INC
Prevention of opportunistic infections in immune-compromised subjects
ActiveUS20100260720A1Reduce the risk of infectionAvoid stickingAntibacterial agentsBiocideFucosylationImmune compromised
This invention relates to a composition suitable for use in the prevention of opportunistic infections in immune-compromised individuals comprising a probiotic Bifidobacterium lactis, Bifidobacterium infantis, Bifidobacterium breve or Bifidobacterium longum and a fucosylated oligosaccharide selected from the group comprising 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose, lacto-N-fucohexaose, fucosyllacto-N-hexaose and fucosyllacto-N-neohexaose. The invention further extends to the use of such a composition in the prevention of opportunistic infections in immune-compromised individuals.
Owner:SOC DES PROD NESTLE SA
Cells of which genome is modified
Owner:KYOWA HAKKO KIRIN CO LTD
Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform
InactiveUS20060024292A1Easily reproducibleAdverse effect can be minimized and avoidedImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntibodyFucose
The present invention relates to immunoglobulin glycoprotein compositions having predominant N-glycan structures on an immunoglobulin glycoprotein which confer a specific effector function. Additionally, the present invention relates to pharmaceutical compositions comprising an antibody having a particular enriched N-glycan structure, wherein said N-glycan structure is Gal2GlcNAc2Man3GlcNAc2 lacking fucose.
Owner:GLYCOFI
Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
InactiveUS20070134759A1High effector functionHighly functionalFungiSugar derivativesGlycosideAntiendomysial antibodies
The present invention provides a process for producing an antibody composition using a cell, which comprises using a cell into which an RNA having activity of suppressing the function of an enzyme relating to the modification of a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex type N-glycoside-linked sugar chain is introduced; the RNA used in the production process; a DNA corresponding to the RNA; a cell in which the RNA or DNA is introduced or expressed; a process for producing the cell; and a method for suppressing the enzyme.
Owner:KYOWA HAKKO KIRIN CO LTD
CCR4-specific antibody composition
InactiveUS20050287138A1Enhanced effector functionEffective treatmentImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsGlycosideComplex type
The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.
Owner:KYOWA HAKKO KOGYO CO LTD
Aad-1 event das-40278-9, related transgenic corn lines, and event-specific identification thereof
ActiveUS20120214975A1Effectively block the fucose de novo pathwayReduce and eliminate allergic reactionImmunoglobulinsOxidoreductasesSugarGenetically modified maize
The present invention relates to cells for producing a molecule lacking fucose, having a reduced amount of fucose, or having other atypical sugars on its glycomoieties. It also relates to methods for producing a molecule lacking fucose, having a reduced amount of fucose, or having other atypical sugars on its glycomoieties using said cells and to molecules obtainable by said methods. The present invention further relates to molecules having an artificial glycosylation pattern.
Owner:PROBIOGEN AG
Method and application for screening ultralow fucose cell line
The invention discloses a method and application for screening an ultralow fucose cell line. The invention provides a method for constructing fucose deficit type host cells capable of expressing an antibody and an IgG-FC fusion protein, a detection method for the fucose activity of the antibody and the IgG-Fc fusion protein, and concrete application of the cell lines. The method provided by the invention is realized by highly-efficient knockout of fucose-based transferase (FUT8) gene in an engineering cell producing the antibodies and the IgG-Fc fusion protein through a TALEN (and / or CRISPR) technology; and through lens culinaris lectin (LCA) pressurizing, gene sequencing and a flow cytometry screening process, the host cells with highly-efficiently knocked-out fucose is obtained. Meanwhile, fucose deficit CHOK1 host cell lines are constructed into stable engineering cell lines capable of expressing antibody proteins; and after the antibody proteins are obtained, glycoform analysis is performed; and results show that fucose knockout efficiency reaches to 99% or above.
Owner:XUANZHU BIOPHARMACEUTICAL CO LTD +1
Establishment and application of CHO cell line for producing fucose-free monoclonal antibody
PendingCN106701823AEdit validSimple and fast operationNucleic acid vectorImmunoglobulinsAntigenWild type
The invention discloses establishment and application of a CHO cell line for producing a fucose-free monoclonal antibody. A CRISPR / Cas9 technology is utilized to encode an FUT8 gene of a CHO cell to obtain the FUT8 gene silenced CHO cell line for stabilizing FUT8 gene deletion (hereinafter referred to as FUT8- / -cell line). By adopting physicochemical property and bioactivity detection of an FUT8- / -cell expressed antibody, a glycoform detection result indicates that fucose of the FUT8- / -cell expressed monoclonal antibody is completely eliminated, a fucose-containing monoclonal antibody expressed by a wild CHO cell serves as a contrast, the affinity with a Fcgamma RIIIa antigen of the fucose-free monoclonal antibody is improved by 7 times, and the ADCC effect is improved by 25 times.
Owner:SHANGHAI JIAO TONG UNIV +2
Three-branched sugar-chain asparagine derivatives, the sugar-chain asparagines, the sugar chains, and processes for producing these
A 3-branched asparagine-linked oligosaccharide derivative of the formula (1) wherein the nitrogen of amino group of asparagine is modified with a lipophilic protective group, biotin group or FITC group; a 3-branched asparagine-linked oligosaccharide derivative which contains at least one fucose in N-acetylglucosamine on the nonreducing terminal side of the asparagine-linked oligosaccharide of the derivative; asparagine-linked oligosaccharides and oligosaccharides thereof wherein Q is a lipophilic protective group, biotin group or FITC group.
Owner:GLYTECH
Sugar chain asparagine derivatives, sugar chain asparagine, sugar chain, and processes for producing these
ActiveUS20060228784A1Easy to prepareEfficiently and in large amountOrganic active ingredientsBiocideN-AcetylglucosamineSugar
An asparagine-linked α2,3-oligosaccharide having undeca- to hepta-saccharides, an asparagine-linked α2,6-oligosaccharide having undeca- to hepta-saccharides and containing fluorine and an asparagine-linked oligosaccharide derivative containing at least one fucose in N-acetylglucosamine on the nonreducing terminal side of an asparagine-linked oligosaccharide wherein the asparagine has amino group protected with a lipophilic protective group, and a process for producing these compounds.
Owner:GLYTECH
Fucosyllactose as breast milk identical non-digestible oligosaccharide with new functional benefit
InactiveUS20120177691A1Simple structureIncrease NK cell activityBiocideOrganic active ingredientsNutritional compositionPhysiology
Owner:NUTRICIA
Production of galactosylated glycoproteins in lower eukaryotes
InactiveUS7795002B2Reducing and eliminating activityEfficient workSugar derivativesPeptide/protein ingredientsUDP galactoseSialic acid
The present invention provides a novel lower eukaryotic host cell producing human-like glycoproteins characterized as having a terminal β-galactose residue and essentially lacking fucose and sialic acid residues. The present invention also provides a method for catalyzing the transfer of a galactose residue from UDP-galactose onto an acceptor substrate in a recombinant lower eukaryotic host cell, which can be used as a therapeutic glycoprotein.
Owner:GLYCOFI
Glycoprotein compositions
Owner:GENENTECH INC
Antibody composition-containing medicament
A medicament for treating a patient who cannot be cured with a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain, and a method for screening the patient by using the medicament.
Owner:KYOWA HAKKO KIRIN CO LTD
Method of producing recombinant antithrombin III composition
Owner:KYOWA HAKKO KIRIN CO LTD
Glucose-responsive insulin conjugates
Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein the saccharide for at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and / or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.
Owner:MERCK SHARP & DOHME LLC
Anti-Glypican 3 Antibody Having Modified Sugar Chain
InactiveUS20080124330A1Improve the level ofImmunoglobulins against animals/humansAntibody ingredientsAnticarcinogenSugar
An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2 / 0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.
Owner:CHUGAI PHARMA CO LTD
Separation of sugars
InactiveUS7037378B2Avoid insufficient puritySugar derivativesSugar productsChromatographic separationDeoxy sugar
Owner:DANISCO SWEETENERS
Method of Enhancing of Binding Activity of Antibody Composition to FcGamma Receptor IIIa
A method for enhancing a binding activity of an antibody composition to Fcγ receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcγ receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.
Owner:KYOWA HAKKO KIRIN CO LTD
Fucosylated glycosaminoglycan derivative and preparation method thereof
InactiveCN102329397APotent anticoagulant activityOrganic active ingredientsBlood disorderOrganosulfateCarboxylic ester
The invention discloses a carboxylic ester of fucosylated glycosaminoglycan (CEFG) with anticoagulation activity, a pharmaceutically acceptable salt thereof, a preparation method of the CEFG and the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the CEFG or the salt thereof, and application of the pharmaceutical composition in preparation of anticoagulants. The monosaccharides for preparing the CEFG comprise D-glucuronic acid or D-glucuronate (D-GlcU), D-2-deoxy-2-acetyl galactosamine sulfate (D-GalNAcS) and L-fucose sulfate (L-FucS), wherein the molar ratio of D-GlcU to D-GalNAc to L-Fuc to -OSO3<-> is 1:(1+ / -0.3):(1+ / -0.3):(3.5+ / -0.5); the esterification degree of the D-GlcU is not lower than 20%; and the weight average molecular weight of the CEFG is 3000-20000 Da. The glycosylated chondroitin sulfate esterification derivative has strong anticoagulation activity, and can be applied in preparation of drugs for preventing and / or treating thrombotic diseases.
Owner:KUNMING INST OF BOTANY - CHINESE ACAD OF SCI
Skin care composition and application thereof
InactiveCN103271839ADelay agingGood skin careCosmetic preparationsToilet preparationsMedicineCoenzyme Q10
The invention discloses a skin care composition, wherein the composition mainly comprises the following materials according to parts by weight: 0.1-5 parts of L-fucose, 0.05-5 parts of coenzyme Q10, 0.1-5 parts of hyaluronic acid, 0.05-2 parts of ceramide, and 1-25 parts of mPEG. The skin care composition can be prepared into any common skin care preparation. In addition, the invention further discloses application of the composition in preparation of the skin care composition having the functions of preventing aging and skin inflammation and moisturizing.
Owner:西宝生物科技(上海)股份有限公司
Recombinant expression plasmid vector for producing fucose-based lactose, metabolic engineering bacteria, and production method
The invention relates to a recombinant expression plasmid vector for producing fucose-based lactose, metabolic engineering bacteria, and a production method and belongs to the fields of metabolic engineering, food fermentation and the like. In the invention, genes for encoding GDP-mannose-6-dehydrogenase, GDP-fucose synthetase, lactose permease, and alpha-1,2-fucose transferase or alpha-1,3-fucosetransferase, which are required in a de-novo synthesis route of the fucose-based lactose, are expressed in corynebacterium glutamicum, so that recombinant corynebacterium glutamicum is constructed toachieve synthesis of 2'-fucose-based lactose or 3'-fucose-based lactose. In addition, by over-expression of the genes for encoding phosphomannose isomerase, phosphomannose mutase, and mannose-1-phosphate guanylyltransferase in the corynebacterium glutamicum, high yield of the fucose-based lactose is achieved. According to the method, the engineering bacteria can synthesize the fucose-based lactose by means of glucose or glycerol, has advantages of high growth speed and good safety, and has significant industrial potential.
Owner:JIANGSU UNIV
Sea pumpkin and sea pumpkin product sea pumpkin polysaccharide content determination method
InactiveCN101285826AStrong absorption capacitySimple and fast operationComponent separationBiological testingHydrolysisPeak area
The invention discloses a method for determining sea cucumber polysaccharide content in a sea cucumber or a sea cucumber product. The method is characterized in that the sea cucumber or the sea cucumber product is enzymolyzed by protease; the sea cucumber polysaccharide produced by the enzymolysis is separated out by adopting alcohol precipitation; then tested solution is prepared by hydrolysis of trifluoroacetate; the tested solution is prepared into fucose standard water solution which is derived by 1-phenyl-3-methyl-5-pyrazolone; the peak area of fucose derivative in the obtained derivatives is measured by high performance liquid chromatography; and the sea cucumber polysaccharide content in the sea cucumber product is obtained by calculating with the fucose as a reference. The invention provides a simple, accurate, reliable and standardized quantitative analysis method for determining the sea cucumber polysaccharide in various sea cucumbers and sea cucumber products.
Owner:OCEAN UNIV OF CHINA
Anti-glypican 3 antibody having modified sugar chain
An anti-glypican 3 antibody with modified sugar chains, more specifically, an anti-glypican 3 antibody lacking fucose is provided. The anti-glypican 3 antibody with modified sugar chains of the present invention may be produced by a process comprising introducing a nucleic acid encoding an anti-glypican 3 antibody into host cells with reduced fucose addition capability, such as YB2 / 0 cells and cells lacking a fucose transporter. The anti-glypican 3 antibody with modified sugar chains of the present invention has a high level of cytotoxic activity and therefore is useful as a cell growth inhibitor such as an anticancer agent.
Owner:CHUGAI PHARMA CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com